Data / Crowdfunding / North Carolina / Vast Therapeutics, Inc.
Vast Therapeutics, Inc.: crowdfunding raise on StartEngine Primary, LLC, $20,800 to $1,235,000 (2024)
Vast Therapeutics, Inc., a corporation in Morrisville, NC, filed a Form C with the SEC on December 16, 2024 to raise $20,800 to $1,235,000 in Series B Preferred Stock through StartEngine Primary, LLC. The offering closed on March 17, 2025. In its most recent fiscal year it reported $227,645 in revenue and a net loss of $6,110,183, with 7 employees.
SpecStream is the live web data engine for teams and agents. It reads every Form C on SEC EDGAR each morning, and this page is that reading. Ask for your own cut (a portal, a state, a size, a revenue range) and new raises arrive in your sheet, CRM, Slack or agent as they land.
- Website
- www.vasttherapeutics.com
- Funding portal
- StartEngine Primary, LLC
- Address
- 615 Davis Dr. Suite 800, Morrisville, NC 27560
- Legal form
- Corporation
- Jurisdiction
- DE
- Incorporated
- April 5, 2017
- SEC CIK
- 0002041605
Offering terms
From the amendment filed December 16, 2024.
- Security
- Series B Preferred Stock
- Price
- $1.04
- Target
- $20,800
- Maximum
- $1,235,000
- Deadline
- March 17, 2025
- Portal compensation
- 7 - 13 percent
Financials
From the Form C-AR filed May 1, 2025.
| Most recent fiscal year | Prior fiscal year | Source | |
|---|---|---|---|
| Revenue | $227,645 | $737,317 | sec.gov |
| Cost of goods sold | $0 | $0 | sec.gov |
| Net income | $-6,110,183 | $-7,536,759 | sec.gov |
| Taxes paid | $0 | $0 | sec.gov |
| Total assets | $41,634,211 | $44,528,729 | sec.gov |
| Cash | $31,466 | $98,317 | sec.gov |
| Accounts receivable | $21,372 | $207,524 | sec.gov |
| Short-term debt | $0 | $0 | sec.gov |
| Long-term debt | $12,899,653 | $9,958,976 | sec.gov |
Filings
| Filed | Filing | Target | Maximum | Deadline | Note | Source |
|---|---|---|---|---|---|---|
| May 1, 2025 | Annual report | Not listed | Not listed | sec.gov | ||
| March 25, 2025 | Progress update | $20,800 | $1,235,000 | March 17, 2025 | The issuer has closed on $439,487.22 and 539,229 shares. | sec.gov |
| December 16, 2024 | Amendment | $20,800 | $1,235,000 | March 17, 2025 | Reduced minimum to $20,800, increased maximum to $1,235,000, adjusted use of proceeds, extended offering end date, disclosed $90K insider investments, added $11M related party debt, added KNOW Bio LLC ownership, and added a perk. | sec.gov |
| December 10, 2024 | Progress update | $123,999 | $1,235,000 | February 17, 2025 | The issuer has raised over 100% ($162,948.15) of the offering target amount ($123,999.20). | sec.gov |
| December 5, 2024 | Progress update | $123,999 | $1,235,000 | February 17, 2025 | The issuer has raised over 50% ($105,840.69) of the offering target amount ($123,999.20). | sec.gov |
| November 19, 2024 | Offering | $123,999 | $1,235,000 | February 17, 2025 | sec.gov |
Updated May 1, 2025. Read from SEC EDGAR. Public domain (U.S. government work). Financials are as each company reported them in its Form C, unaudited unless the filing says otherwise. Websites are the ones the companies declared to the SEC. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.